# EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

> **NCT04509726** · PHASE1,PHASE2 · COMPLETED · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 9 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** EBV-specific TCR-T cell with cytokine auto-secreting element

## Key facts

- **NCT ID:** NCT04509726
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04509726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04509726, "EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04509726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*